Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | ABL1 | P00519 | 11/20 | 1.00 |
| ▸ | ABL2 | P42684 | 11/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.81 |
| ▸ | LCK | P06239 | 4/20 | 0.77 |
| ▸ | KDR | P35968 | 3/20 | 0.77 |
| ▸ | TEK | Q02763 | 3/20 | 0.77 |
| ▸ | LYN | P07948 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | RGS12 | O14924 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | GMNN | O75496 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5936173 | 0.96 | SRC (0.97) | SRCEGFRABL1ABL2RIPK2 | |
| SCHEMBL24458610 | 0.90 | SRC (0.96) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL8320799 | 0.88 | SRC (0.81) | SRCEGFRABL1ABL2RIPK2 | |
| Hydrochloric Acid SCHEMBL7098308 | 0.88 | SRC (0.85) | SRCEGFRABL1ABL2RIPK2 | |
| SCHEMBL13020005 | 0.87 | SRC (0.78) | SRCEGFRABL1ABL2RIPK2 | |
| SCHEMBL29920993 | 0.87 | SRC (1.00) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL378454 | 0.87 | SRC (1.00) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL18044541 | 0.87 | SRC (0.81) | SRCEGFRABL1ABL2RIPK2 | |
| SCHEMBL8320765 | 0.86 | SRC (0.75) | SRCEGFRABL1ABL2RIPK2 | |
| SCHEMBL23834505 | 0.86 | SRC (0.98) | SRCEGFRABL1ABL2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491923-A2 | Combinations of therapeutic agents for treating cancer | Novartis AG (CH) | 2012-08-29 | — | — | EP | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| US-20100069458-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | claimed |
| CN-101626758-A | Combination of LBH589 and other therapeutic agents for the treatment of cancer | NOVARTIS AG | 2010-01-13 | — | — | CN | claimed |
| EP-2120900-A2 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2009-11-25 | — | — | EP | claimed |
| WO-2008100985-A2 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2008-08-21 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | SRC 1586/4885EGFR 3481/4885ABL1 746/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | SRC 2088/4885EGFR 1372/4885ABL1 3228/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | SRC 1968/4885EGFR 1496/4885ABL1 785/4885 |
| US-20100069458-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | MCL1, BAD, LPXN | SRC 3382/4885EGFR 554/4885ABL1 468/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | SRC 4123/4885EGFR 2453/4885ABL1 4855/4885 |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | TYMP, DPYD, TYMS | SRC 2626/4885EGFR 2559/4885ABL1 1490/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | SRC 3186/4885EGFR 2685/4885ABL1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.